• 1
    Huang H, He X. Wnt/β-catenin signaling: new (and old) players and new insight. Curr Opin Cell Biol. 2008;20:1195.
  • 2
    Wagner ER, Zhu G, Zhang BQ, Luo Q, Shi Q, Huang E, Gao Y, Gao JL, Kim SH, Rastegar F, Yang K, He BC, Chen L, Zuo GW, Bi Y, Su Y, Luo J, Luo X, Huang J, Deng ZL, Reid RR, Luu HH, Haydon RC, He TC. The therapeutic potential of the Wnt signaling pathway in bone disorders. Curr Mol Pharmacol. 2011;4(1):1425.
  • 3
    Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:57789.
  • 4
    Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME. A 52-kb deletion in the SOST-MEOXI intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110:14452.
  • 5
    Balemans W, Patel N, Ebeling M, van Hul E, Wuyts W, Lacza C, Disozegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery BM, Foernzler D, van Hul W. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39:917.
  • 6
    Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shlhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):57888.
  • 7
    Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density and bone strength. J Bone Miner Res. 2010;25(5):94859.
  • 8
    Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010;25(11):24128.
  • 9
    Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):1926.
  • 10
    Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R. Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2006;21:173849.
  • 11
    Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. Novel mechanism of Wnt signaling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol. 2001;3:6836.
  • 12
    Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM. and others. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:51323.
  • 13
    Politou M, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006;119:172831.
  • 14
    Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clezardin P, Garnero P. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer. 2007;97:96470.
  • 15
    Rouzi AA, Al-Sibiani SA, Al-Senani NS, Radaddi RM, Ardawi M-SM. Independent predictors of osteoporosis-related fractures among healthy Saudi postmenopausal women: The CEOR Study. Bone. 2012;50:71322.
  • 16
    International Statistical Classification of Diseases and Related-Health Problems 10th rev. ICD-10-CM. Geneva: World Health Organization; 1992.
  • 17
    Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using semi-quantitative technique. J Bone Miner Res. 1993;8:113748.
  • 18
    Ardawi M-SM, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011;26(12):281222.
  • 19
    Ardawi M-SM, Al-Sibiany AM, Bakhsh TM, Rouzi AA, Qari MH. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int. 2012;23(6):178997.
  • 20
    Modder UIL, Clowes JA, Hoey K, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S. Regulation of circulating sclerostin levels by sex steroids in women and men. J Bone Miner Res. 2011;26(1):2734.
  • 21
    Ardawi M-SM, Maimani AA, Bahksh TM, Rouzi AA, Qari MH, Radaddi RM. Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study. Bone. 2010;47:80414.
  • 22
    Hennekens GH, Buring JE. Measure of disease frequency and association. In: SL, Mayrent, editor. Epidemiology in medicine. Boston: Little, Brown and Company; p. 8795. 1997.
  • 23
    Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ 3rd, Khosla S. Relation of age, gender and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26(2):3739.
  • 24
    Arasu A, Cawthon PM, Lui LY, Do TP, Arora PS, Cauley JA, Ensrud KE, Cummings SR. The Study of Osteoporotic Fractures Research Group. Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab. 2012 Jun; 97(6):202732.
  • 25
    Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in post-menopausal women: the OFELY study. Osteoporos Int. Epub. 2012 Apr 14.
  • 26
    Ivaska KK, Gerdhem P, Vaananen HK, Akesson K, Obrant KJ. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res. 2010;25(2):393403.
  • 27
    Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:263543.
  • 28
    Rochefort GY, Pallu S, Benhamou CL. Osteocytes: the unrecognized side of bone tissue. Osteoporos Int. 2010;21:145769.
  • 29
    Giovanni S, Marzetti E, Borst SE, Leeuwenbugh C. Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults. Mech Ageing Dev. 2008;129:593601.
  • 30
    Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A. Sclerostin and its association with physical activity, age, gender, body composition and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012;97:14854.
  • 31
    Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010;95:224853.
  • 32
    Bergstrom I, Parini P, Gustafsson SA, Andersson G, Brink J. Physical training increases osteoprotegerin in postmenopausal women. J Bone Miner Metab. 2012;30:2027.
  • 33
    Moayyeri A. The association between physical activity and osteoporotic fractures: a review of the evidence and implication for future research. Ann Epidemiol. 2008;18(1):82735.
  • 34
    Rauner M, Sipos W, Pietschmann P. Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation. Age (Dordr). 2008;30:27382.
  • 35
    Sheng Z, Tong D, Ou Y, Zhang H, Zhang Z, Li S, Zhou J, Zhang J, Liao E. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol (Oxf). 2012 Jun; 76(6):797801.
  • 36
    Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95:19917.
  • 37
    Lewiecki EM. Sclerostin: a novel target for intervention in the treatment of osteoporosis. Discovery Med. 2011;12(65):26373.
  • 38
    Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet. 2003;63:1927.
  • 39
    Darke MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010;95:505662.